Savara’s (SVRA) In-Line Rating Reiterated at Evercore ISI

Savara (NASDAQ:SVRA)‘s stock had its “in-line” rating restated by analysts at Evercore ISI in a research report issued on Wednesday,Benzinga reports. They currently have a $5.00 price target on the stock, down from their prior price target of $7.00. Evercore ISI’s price objective suggests a potential upside of 30.55% from the company’s current price.

A number of other brokerages have also weighed in on SVRA. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Savara in a research note on Tuesday, October 1st. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of Savara in a research note on Tuesday, October 8th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.83.

Savara Trading Down 5.9 %

Savara stock opened at $3.83 on Wednesday. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $3.97 and a two-hundred day moving average price of $4.22. The firm has a market capitalization of $630.42 million, a price-to-earnings ratio of -9.12 and a beta of 1.02. Savara has a 52-week low of $3.28 and a 52-week high of $5.70.

Savara (NASDAQ:SVRA) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). Sell-side analysts expect that Savara will post -0.44 earnings per share for the current year.

Hedge Funds Weigh In On Savara

Hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC raised its stake in shares of Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after acquiring an additional 2,114 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Savara by 15.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock valued at $168,000 after purchasing an additional 4,625 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Savara by 14.9% in the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock valued at $166,000 after acquiring an additional 5,335 shares in the last quarter. Principal Financial Group Inc. grew its stake in Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co bought a new position in Savara in the 1st quarter valued at approximately $35,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.